Article
Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
Journal of hepatology - 1 Jun 2001
Naoumov N V, Lopes A R, Burra P, Caccamo L, Iemmolo R M, de Man R A, Bassendine M, O'Grady J G, Portmann B C, Anschuetz G, Barrett C A, Williams R, Atkins M
Abstract excerpt
BACKGROUND/AIMS: The long-term prophylaxis of hepatitis B after liver transplantation requires further optimization. In a randomized trial we investigated a regimen where the initially given hepatitis B immunoglobulin (HBIg) is replaced by long-term lamivudine treatment. METHODS: Twenty-four liver transplant recipients (all HBsAg-positive/HBV DNA-negative before transplantation), who had received HBIg for at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.